Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Employees - 5, CEO - Mr. Lewis H. Bender M.A., M.B.A., M.S., Sector - Healthcare, Country - US, Market Cap - 9.16M

Altman ZScore(max is 10): -26.02, Piotroski Score(max is 10): 1, Working Capital: $1608000, Total Assets: $4783000, Retained Earnings: $-66783000, EBIT: -16325000, Total Liabilities: $1865000, Revenue: $0

AryaFin Target Price - $0.17 - Current Price $0.60 - Analyst Target Price $10.38